Navigation Links
M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients
Date:10/26/2007

SUNNYVALE, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company is partnering with The University of Texas M. D. Anderson Cancer Center in Houston, Texas to launch a prospective clinical study to compare treatment outcomes in early-stage operable lung cancer. Patients in the study will be randomly assigned to traditional surgery or CyberKnife(R) Robotic Radiosurgery for their treatment.

In the past several years evidence has grown showing excellent outcomes in the treatment of lung tumors with high-dose radiation delivered in three or four treatments. Study results on operable patients treated by these short courses have demonstrated survival rates and local control rates similar to those of traditional surgery. As the medical community moves toward adoption of more minimally invasive alternatives to treatment, data that compare outcomes of surgery to less invasive treatment options, such as radiosurgery, become extremely important.

"We feel the time is right to explore less invasive alternatives for early stage lung cancer patients," said Jack Roth, M.D., professor and Bud Johnson Clinical Distinguished Chair, Department of Thoracic & Cardiovascular Surgery at M. D. Anderson and the study's principal investigator. "The results achieved with radiosurgery appear to be comparable to those achieved with traditional surgery for early stage lung cancer patients and a randomized clinical trial is required to accurately compare results from the two. To do so, we must use a uniform platform to assure the highest possibility of cure for these patients, which is why we are partnering with Accuray to use the Cyber
'/>"/>

SOURCE Accuray Incorporated
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
2. M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data at the AACR Annual Meeting
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Protox Announces Positive Clinical Data from Prostate Cancer Study
8. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
9. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
10. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
11. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10DSS Research Announces Senior Health Risk Assessment 28SrHRA 29 28TM 29 58537 1DSS Research Announces Senior Health Risk Assessment 28SrHRA 29 28TM 29 58537 2Pan American Life Insurance Group Plans to Complete Coverage in Central America With Entry Into Costa Rica 3B Company Files Request for Authorization 58534 1Pan American Life Insurance Group Plans to Complete Coverage in Central America With Entry Into Costa Rica 3B Company Files Request for Authorization 58534 2Sport Science Lab Maintains That Injury to USC Football Player is Symptomatic of the Dangers of Conventional Weight Training 58530 1Sport Science Lab Maintains That Injury to USC Football Player is Symptomatic of the Dangers of Conventional Weight Training 58530 2